Cytopoint™

Helping improve quality of life with CYTOPOINT^™

It’s an old story: A patient with canine atopic dermatitis is itching, scratching, chewing and then itching some more. Both the dog and the client are beside themselves. They’re sleep-deprived. They can’t enjoy each other’s company. And you want to help.

CYTOPOINT, a novel biologic therapy, brings in a new era in relieving the clinical signs associated with atopic dermatitis in dogs.

This monoclonal antibody (mAb) therapy:

	Begins working within 1 day.*
	Provides 4–8 weeks of relief* from clinical signs of canine atopic dermatitis.
	Allows time for damaged skin to heal.¹
	Targets and neutralizes interleukin (IL)-31, a key cytokine in the cycle of itch and inflammation.²
	Is safe for dogs of all ages and can be used with many common medications.^3,4

Relieving clinical signs of canine atopic dermatitis not only helps improve quality of life for dogs and their families, but can also strengthen the client-veterinarian bond. Veterinarians and their clients report that dogs treated with CYTOPOINT seem much more like their old selves. Sophie is one of those dogs, as Dr. Liz Hardesty and Rick, Sophie’s owner, happily discovered.

Indication:
CYTOPOINT aids in the reduction of clinical signs associated with atopic dermatitis in dogs.

*Repeat administration every 4–8 weeks, as needed, in the individual patient.¹
1. Data on file, Study Report No. C863R-US-12-018, Zoetis Inc.
2. Gonzales AJ, Humphrey WR, Messamore JE, et al. Interleukin-31: its role in canine pruritus and naturally occurring canine atopic dermatitis. Vet Dermatol. 2013;24(1):48-53. doi:10.1111/j.1365-3164.2012.01098.x.
3. Data on file, Study Report No. C362N-US-13-042, Zoetis Inc.
4. Data on file, Study Report No. C961R-US-13-051, Zoetis Inc.

All trademarks are the property of Zoetis Services LLC. or a related company or a licensor unless otherwise noted. ©2017 Zoetis Services LLC. All rights reserved. CYT‑00244A

This is an advertisement from Zoetis Inc.
10 Sylvan Way
Parsippany, New Jersey 07054

To opt out of future messages from DVM360 on behalf of CYTOPOINT click here.